Related Experiment Video
Updated: Jun 19, 2026

Isolation of Culturable Yeasts and Molds from Soils to Investigate Fungal Population Structure
Published on: May 27, 2022
Azole-resistance in Aspergillus: proposed nomenclature and breakpoints
Paul E Verweij1, Susan J Howard, Willem J G Melchers
1Department of Medical Microbiology, Radboud University, Nijmegen Medical Centre, The Netherlands.
Abstract:
Reports of itraconazole resistance in Aspergillus fumigatus have been more frequent since the millennium. Identifying azole resistance is critically method dependent; nevertheless reproducible methods, reflective of in vivo outcome, are now in routine use. Some isolates also have elevated MICs to posaconazole and voriconazole. Multiple mechanisms of resistance are now known to be responsible, with differing degrees of azole cross-resistance, including mutations in the Cyp51A gene at G54, L98+TR, G138, M220, G448. Establishing breakpoints for Aspergillus is probably impossible with clinical data alone for multiple reasons yet there is an urgent need to do so. We propose the following breakpoints for A. fumigatus complex using the proposed EUCAST susceptibility testing methodology: for itraconazole and voriconazole, <2 mg/L (susceptible), 2 mg/L (intermediate) and >2 mg/L (resistant); for posaconazole, <0.25, 0.5 and >0.5 mg/L respectively. We recognize that additional work will be needed to confirm these proposed breakpoints, including in vivo and clinical correlative responses. We also propose nomenclature for genotypic resistance, in the event an isolate is not cultured, typified by ITZgR, VCZgI, POSgR (G54W) indicating that the isolate has a G54W substitution with a corresponding phenotype of resistance to itraconazole and posaconazole and intermediate susceptibility to voriconazole.
Insights
Reports of itraconazole resistance in Aspergillus fumigatus are increasing. New breakpoints for azole antifungal susceptibility testing are proposed to guide treatment, alongside nomenclature for genotypic resistance.
Area of Science:
- Medical Mycology
- Antimicrobial Resistance
Background:
- Increasing reports of itraconazole resistance in Aspergillus fumigatus since 2000.
- Azole resistance identification is method-dependent, but reproducible methods are available.
- Some Aspergillus isolates exhibit reduced susceptibility to posaconazole and voriconazole.
Purpose of the Study:
- To propose clinical breakpoints for azole antifungal susceptibility testing in Aspergillus fumigatus.
- To establish standardized nomenclature for genotypic azole resistance in Aspergillus.
Main Methods:
- Utilized the proposed EUCAST susceptibility testing methodology.
- Determined minimum inhibitory concentrations (MICs) for itraconazole, voriconazole, and posaconazole.
- Proposed nomenclature for genotypic resistance, e.g., ITZgR, VCZgI, POSgR (G54W).
Main Results:
- Proposed breakpoints for itraconazole and voriconazole: susceptible (<2 mg/L), intermediate (2 mg/L), resistant (>2 mg/L).
- Proposed breakpoints for posaconazole: susceptible (<0.25 mg/L), intermediate (0.5 mg/L), resistant (>0.5 mg/L).
- Identified multiple resistance mechanisms, including Cyp51A gene mutations (e.g., G54W), conferring cross-resistance.
Conclusions:
- Proposed breakpoints require further validation with in vivo and clinical data.
- Standardized breakpoints and genotypic nomenclature are crucial for managing azole-resistant Aspergillus infections.
- Accurate susceptibility testing is vital for effective antifungal therapy in aspergillosis.
Related Concept Videos
Fungal Phylum Ascomycota
Antifungal Agents
Nomenclature of Aryl and Heterocyclic Amines
Fungal Group Zygomycota
